Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Castelli, J.; Bari, Berardino De; Depeursinge, Adrien; Simon, Antoine; Devillers, Anne; Jimenez, G.; Prior, John O.; Özşahin, Mahmut; Crevoisier, R. de; Bourhis, Jean

doi:10.1016/j.critrevonc.2016.10.009

Cited by 57 publications

(54 citation statements)

References 56 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…tumor metabolism). [27–29] FDG-PET/CT has been successfully used for HNSCC radiation treatment planning purposes,[30] however, its effective use for dose escalation requires a validation of the geometric correlation between the origin of posttreatment disease failure, pretreatment FDG-PET uptake, planning target volumes, and radiation dose, which is the main aim of the current study. The uncertainties and limitations of PET are well known[31].…”

Section: Discussionmentioning

confidence: 99%

Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions

Mohamed

Cárdenas

Garden

et al. 2017

Radiotherapy and Oncology

View full text Add to dashboard Cite

Background To identify the radio-resistant subvolumes in pretreatment FDG-PET by mapping the spatial location of the origin of tumor recurrence after IMRT for head-and-neck squamous cell cancer to the pretreatment FDG-PET/CT. Methods Patients with local/regional recurrence after IMRT with available FDG-PET/CT and post-failure CT were included. For each patient, both pre-therapy PET/CT and recurrence CT were co-registered with the planning CT (pCT). A 4-mm radius was added to the centroid of mapped recurrence growth target volumes (rGTV’s) to create recurrence nidus-volumes (NVs). The overlap between boost-tumor-volumes (BTV) representing different SUV thresholds/margins combinations and NVs was measured. Results Forty-seven patients were eligible. Forty-two (89.4%) had type A central high dose failure. Twenty-six (48%) of type A rGTVs were at the primary site and 28 (52%) were at the nodal site. The mean dose of type A rGTVs was 71 Gy. BTV consisting of 50% of the maximum SUV plus 10mm margin was the best subvolume for dose boosting due to high coverage of primary site NVs (92.3%), low average relative volume to CTV1 (41%), and least average percent voxels outside CTV1 (19%). Conclusions The majority of loco-regional recurrences originate in the regions of central-high-dose. When correlated with pretreatment FDG-PET, the majority of recurrences originated in an area that would be covered by additional 10 mm margin on the volume of 50% of the maximum FDG uptake.

show abstract

Section: Discussionmentioning

confidence: 99%

Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions

Mohamed

Cárdenas

Garden

et al. 2017

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…Insbesondere der herausgehobene negative prädiktive Wert (NPV) der PET/CT zeigte sich auch in der PET-NECK- Studie [46].…”

Section: [ 18 F]-fdg-pet/ct In Der Verlaufskontrolle Und Nachsorgeunclassified

PET-basierte Bestrahlungsplanung

Grunert¹,

Prasad²

2020

Der Nuklearmediziner

View full text Add to dashboard Cite

Head and neck tumours are associated with high morbidity and mortality. Radiotherapy is an integral part of the treatment of these tumours and [18F]-FDG-PET/CT or PET/MRI is becoming increasingly important in the personalised treatment of head and neck cancer. Advanced tumour stage radiotherapy is combined with chemotherapy and/or surgery. The paper deals with the elementary importance of measuring the exact tumour extent and the resulting determination of the tumour volumes in image-based radiotherapy planning as the basis for successful irradiation. The PET/CT-based target volume definition results in target volume reduction with consecutive protection of risk organs and healthy tissue. Increased glucose metabolism and hypoxic states of cancerous lesions allows PET/CT to correctly identify tumour regions and thereby helps in potential dose escalation for tumour control. PET/MRI shows promising results in the diagnosis of relapses after radiotherapy, but requires further evaluation in larger studies. The [18F]-FDG-PET/CT is ideally suited for therapy evaluation and recurrence diagnosis and has found its way into the ambulatory reimbursement system with some indications due to randomised studies with the highest level of evidence. In addition, the increasing use of machine learning in radiation therapy is emphasised.

show abstract

“…Tedavi sonrası PET/BT yapılan Baş-boyun kanserli hastaların değerlendirildiği çalışmaların gözden geçirildiği bir derlemede; tedavi sonrası yüksek SUV max değeri olan hastaların kötü sonuçlarla korele olduğu görülmüş. (10).…”

Section: Introductionunclassified

Evaluation of the Response to Radiotherapy With Positron Emission Tomography/Computer Tomography in Head and Neck Carcinoma

Kekilli¹,

Tunali²

2019

Acta Oncol Tur.

View full text Add to dashboard Cite

Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy

Cited by 57 publications

References 56 publications

Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions

Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions

PET-basierte Bestrahlungsplanung

Evaluation of the Response to Radiotherapy With Positron Emission Tomography/Computer Tomography in Head and Neck Carcinoma

Contact Info

Product

Resources

About